Agenus Stock (NASDAQ:AGEN)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$2.57

52W Range

$2.50 - $19.69

50D Avg

$4.59

200D Avg

$9.40

Market Cap

$62.64M

Avg Vol (3M)

$438.65K

Beta

1.39

Div Yield

-

AGEN Company Profile


Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

389

IPO Date

Feb 08, 2000

Website

AGEN Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Non Cash Royalty Revenue$114.57M--
License Fee Revenue$25.00M--
Research And Development Revenue-$1.60M$1.20M
Non Cash Royalty Revenue Related To The Sale Of Future Royalties And Milestone-$45.28M-
Revenue--$6.70M
Product And Service Other--$184.00K

Fiscal year ends in Dec 23 | Currency in USD

AGEN Financial Summary


Dec 23Dec 22Dec 21
Revenue$156.31M$98.02M$295.67M
Operating Income$-160.10M$-179.43M$42.28M
Net Income$-257.44M$-271.51M$-94.70M
EBITDA$785.91M$-160.72M$49.07M
Basic EPS$-0.69$-0.96$-0.41
Diluted EPS$-0.69$-0.96$-0.41

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Nov 12, 24 | 10:41 AM
Q2 24Aug 08, 24 | 12:32 PM
Q1 24May 07, 24 | 1:45 PM

Peer Comparison


TickerCompany
XFORX4 Pharmaceuticals, Inc.
TGTXTG Therapeutics, Inc.
MREOMereo BioPharma Group plc
ADCTADC Therapeutics SA
EWTXEdgewise Therapeutics, Inc.
PDSBPDS Biotechnology Corporation
MRKRMarker Therapeutics, Inc.
ADAPAdaptimmune Therapeutics plc
VKTXViking Therapeutics, Inc.
AFMDAffimed N.V.
LPTXLeap Therapeutics, Inc.
PIRSPieris Pharmaceuticals, Inc.
MDGLMadrigal Pharmaceuticals, Inc.